Vanta Bioscience Ltd Share Price

Description

• Vanta Bioscience Limited was originally incorporated as a private limited company on 29th April 2016 with the name `Vanta Bioscience Private Limited`. The Company was converted into a public limited company and consequently, the name of the Company was changed to `Vanta Bioscience Limited` on 17th March 2017. The Promoters of the Company are Mohan Krishna Mulakala, Dopesh Raja Mulakala, Dr. Vyasmurti Madhavrao Shingatgeri, Dr. Soumya Simhadri, Shravan Chintapatla, Karishma Mulakala, Sajan Kiran Mulakala, Pradeep Chowdary and Dr. Chandrasekhar Rao Simhadri. Vanta Bioscience(VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. VBS entered into an asset transfer agreement dated February 18, 2016 with Kemin Industries South Asia Private Limited, Chennai for the purchase of fully operational toxicology facility Vanta Bioscience` situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai. The Company has taken possession of the said preclinical CRO facility at Gummidipundi, Chennai and has commenced commercial operations thereat from April 1, 2017. Currently the company is mainly doing previous pending research work and are also getting new work from existing clients of Vanta Bioscience` erstwhile division of Kemin Industries South Asia Private Limited. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. The data generated from these studies are submitted to regulatory agencies worldwide before they are put in use for the consumption of domestic animals and human being. In addition, VBS also conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.

• Vanta Bioscience Limited was originally incorporated as a private limited company on 29th April 2016 with the name `Vanta Bioscience Private Limited`. The Company was converted into a public limited company and consequently, the name of the Company was changed to `Vanta Bioscience Limited` on 17th March 2017. The Promoters of the Company are Mohan Krishna Mulakala, Dopesh Raja Mulakala, Dr. Vyasmurti Madhavrao Shingatgeri, Dr. Soumya Simhadri, Shravan Chintapatla, Karishma Mulakala, Sajan Kiran Mulakala, Pradeep Chowdary and Dr. Chandrasekhar Rao Simhadri. Vanta Bioscience(VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, it also provides risk assessment services for evaluatingthe safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers. VBS entered into an asset transfer agreement dated February 18, 2016 with Kemin Industries South Asia Private Limited, Chennai for the purchase of fully operational toxicology facility Vanta Bioscience` situated at Plot K2B, SIPCOT Industrial Estate, Gummidipundi, Chennai. The Company has taken possession of the said preclinical CRO facility at Gummidipundi, Chennai and has commenced commercial operations thereat from April 1, 2017. Currently the company is mainly doing previous pending research work and are also getting new work from existing clients of Vanta Bioscience` erstwhile division of Kemin Industries South Asia Private Limited. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives. The data generated from these studies are submitted to regulatory agencies worldwide before they are put in use for the consumption of domestic animals and human being. In addition, VBS also conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.